Edwards Lifesciences Stock Forecast, Price & News

Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences or view top-rated stocks.

How has Edwards Lifesciences' stock price been impacted by COVID-19 (Coronavirus)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EW stock has increased by 66.5% and is now trading at $109.52.
View which stocks have been most impacted by COVID-19.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 5,530,000 shares, a drop of 20.2% from the October 31st total of 6,930,000 shares. Based on an average daily volume of 2,130,000 shares, the short-interest ratio is currently 2.6 days. Currently, 0.9% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Edwards Lifesciences.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) issued its quarterly earnings results on Wednesday, October, 27th. The medical research company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.53 by $0.01. The medical research company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.32 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 28.13% and a net margin of 29.00%. The company's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.51 earnings per share.
View Edwards Lifesciences' earnings history.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share guidance of $2.070-$2.270 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.260. The company issued revenue guidance of $5.20 billion-$5.40 billion, compared to the consensus revenue estimate of $5.32 billion.

What price target have analysts set for EW?

19 analysts have issued 12-month price objectives for Edwards Lifesciences' stock. Their forecasts range from $85.00 to $135.00. On average, they anticipate Edwards Lifesciences' share price to reach $120.00 in the next year. This suggests a possible upside of 9.6% from the stock's current price.
View analysts' price targets for Edwards Lifesciences or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:

• Michael A. Mussallem, Chairman & Chief Executive Officer
• Scott B. Ullem, Chief Financial Officer & Vice President
• Todd J. Brinton, Chief Scientific Officer & VP-Advanced Technology
• Arnold A. Pinkston, Vice President & General Counsel
• Linda J. Park, Secretary, VP & Associate General Counsel

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Who are some of Edwards Lifesciences' key competitors?

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), DexCom (DXCM), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX), Masimo (MASI) and Abiomed (ABMD).
View all of EW's competitors.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), salesforce.com (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.49%), Bank of New York Mellon Corp (3.58%), Wellington Management Group LLP (2.63%), Sands Capital Management LLC (2.17%), Alliancebernstein L.P. (2.05%) and Janus Henderson Group PLC (1.79%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Janus Henderson Group PLC, Wellington Management Group LLP, Mitsubishi UFJ Trust & Banking Corp, Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., Macquarie Group Ltd., and Primecap Management Co. CA. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, and Nicholas J Valeriani.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Arrowstreet Capital Limited Partnership, Lord Abbett & CO. LLC, Massachusetts Financial Services Co. MA, Invesco Ltd., Capital Research Global Investors, Barclays PLC, and AXA S.A..
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $109.52.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $68.38 billion and generates $4.39 billion in revenue each year. The medical research company earns $823.40 million in net income (profit) each year or $2.35 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 14,900 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

Where are Edwards Lifesciences' headquarters?

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500, via email at [email protected], or via fax at 949-250-2525.